Cyient DLM

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA- by ICRA.
• ResultsGrowingIn the Sep 2026 quarter, sales rose 26% and profit rose 6.3% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 52% of the company, about the same as in Sep 2025.
• ValuationNormal for this stockThe share trades at 71.2 times its yearly earnings (P/E), cheaper than 51% of the time in the last 3 years. Its usual P/E is about 73.

Cyient DLM against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)71.2 against a typical 72.2: cheaper than most peers (1st = cheapest).15th of 33
• Sales growth+26.4% against a typical +30.4% from a year earlier.15th of 28
• Profit growth+6.3% against a typical +8.9% from a year earlier.15th of 27
• Share price, 3 months+10.8% against a typical −2%.12th of 32
• Size₹ 5,960.5 Cr. market value against a typical ₹ 4,442.2 Cr. (1st = largest).12th of 28

Exchange filings and their impact on the company.

• 23 Oct 2026Analysts/Institutional Investor Meet/Con. Call UpdatesHigh impactPositivePrice −0.5% that day
  Record Rs 2813 cr order book and 30% H1 revenue growth underpin outlook despite near-term margin pressure from growth investments.

  Cyient DLM reported Q2 FY27 revenue of Rs 393.1 crore, up 26.5% year-on-year, and H1 revenue up 30.2%, with EBITDA of Rs 34.2 crore at 8.7% margin and normalized profit of Rs 15.8 crore. Its order backlog hit a record Rs 2813 crore with a 1.6x book-to-bill for six straight quarters, plus a pipeline of over $1 billion. Management guided FY27 margins at 9-10% due to investments in sales and build-to-spec products, expecting double-digit margins from FY28 as revenue scales.

  Full analysisFiling
• 16 Oct 2026General UpdatesLow impactNeutralPrice −12.9% that day
  Granted 2.73 lakh RSUs/options (~0.35% dilution) with small ESOP cost over vesting.

  Cyient DLM granted 10,000 stock units under its RSU 2023 plan and 2,63,400 options under its Associate Stock Option Plan 2023 to associates. Together the 2.73 lakh shares represent about 0.35% of outstanding shares. The grants will vest over time, helping retention while creating only small future dilution and ESOP expense.

  Full analysisFiling
• 15 Oct 2026Outcome of Board MeetingLow impactNeutralPrice −12.9% on 16 Oct
  Q2 results approved without extractable numbers, new CHRO appointed, and small ~0.35% ESOP grant made.

  Cyient DLM's board on 15 October 2026 approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. It also appointed Mr. Sandip Mishra as Senior VP and Chief Human Resources Officer, and granted 10,000 stock units and 263,400 stock options to associates. The ESOP grant implies only about 0.35% dilution, so no material change to the business outlook over the next year is expected from the disclosed items.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Rajendra Velagapudi

Chief Executive Officer, Managing Director

R. M. Subramanian

Chief Financial Officer

Kaushal Jadia

Senior Vice President, Chief Technology Officer

S. Krithika

Compliance Officer, Company Secretary

Mujeeb Rahiman

Vice President, Head - Operations, India

Suchitra R. C.

Head - EMS

Pooja Jamwal

Head - Corporate Development

Prashant Suresh Mokashi

Head - Program Management